Income statement and cash flow are moderate; balance sheet is weak.
Next earnings: 2026-11-05 (BMO), EPS Forecast: $4.06
Downgraded from Hold to Sell in the Mar 2026 quarter: 49.5 → 47.4 (-2.2). This quarter: -0.8.
Change vs previous quarter.
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others.